ETRA
NASDAQ HealthcareElectra Therapeutics, Inc. - Common stock
Biotechnology
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.
🎯 投资策略评分
ETRA 在各投资策略中的评分。分数越高,越符合该策略目标。
🔍 策略解读
最佳匹配: 🎈 Over-Hyped (69/100) — 此策略 超买股票(潜在做空标的).
评分最低的策略: 🚀 Moon Shot (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
在文本中查找 ETRA in your text
粘贴任何文章、记录或帖子 — 工具将提取 ETRA 以及每一个其他隐藏的股票代码。
免责声明:本数据仅供教育和娱乐用途,不构成金融建议。市场数据可能存在延迟。在做出投资决策之前,请始终进行自己的研究。
数据最后更新: 2026-09-18.